Home/Healthcare/Healthcare IT/Israel Continuous Glucose Monitoring Market

Israel Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The study analyzes the Israel continuous glucose monitoring industry landscape, innovation trends, and adoption dynamics.

$2,850
Single User License
Report OverviewSegmentationTable of ContentsCustomize Report

Request Customization

Tell us your specific requirements and we will customize this report for you.

πŸ“ž

Your data is secure. We do not share information with any third party.

Israel Continuous Glucose Monitoring Market Report

Report IDKSI061615166
PublishedFeb 2026
Pages92
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

The Israel Continuous Glucose Monitoring (CGM) market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 14.6% during the forecast period. This growth is expected to lead the market from USD 14.3 million in 2026 to reach USD 28.3 million by 2031, as detailed in the strategic insights report.

The Israel Continuous Glucose Monitoring market analysis in this report is segmented by both application and end-user. This structured segmentation provides a granular view of market dynamics and helps identify key areas of demand and consumption within the country.

Key growth drivers include the escalating prevalence of type 1 and type 2 diabetes in Israel, with over 536,500 adults affected in 2021, projected to reach 781,000 by 2045. Additionally, continuous product launches by key market players, rising government initiatives promoting diabetic health, and a decreasing cost of CGM devices in the country are significantly propelling market expansion.

The growth of the Israeli CGM market is primarily obstructed by the high price of CGM devices and the prevalent lack of comprehensive reimbursement policies from medical insurance providers in the region. These factors limit accessibility and wider adoption, impacting market expansion during the analysis period.

According to the International Diabetes Federation, 9.9% of Israeli adults, or more than 536,500 people, had diabetes in 2021, a number projected to reach 781,000 by 2045. This high and increasing prevalence, alongside the risk of severe complications, makes CGM devices essential for managing blood glucose levels, thereby directly fueling the market demand.

Yes, the report identifies continuous product launches by key market players as a significant determinant positively influencing the demand for CGM devices in Israel. While specific companies are not detailed in this excerpt, the analysis encompasses their strategic activities and their contribution to market growth.

Need data specifically for your business?Request Custom Research β†’
Related Reports

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon